Background: Prophylactic low-dose hydrocortisone (HC) was found to improve survival without bronchopulmonary dysplasia (BPD) in extremely preterm infants. However, appropriately adjusting for baseline risks of BPD or death might substantially increase the precision of the HC effect size.
Methods: We conducted a secondary analysis of the PREMILOC trial. The treatment effect was evaluated on the primary endpoint through a covariance analysis ANCOVA, adjusting for the baseline covariates using a mixed linear model. Several sensitivity analyses were conducted to assess the potential heterogeneity of the treatment effect across centers and subpopulations.
Results: The interaction between treatment group and baseline risk for BPD or death was not statistically significant (p = 0.498). After adjusting for the patient's probability of BPD-free survival using baseline predictors alone, the HC treatment exhibited a highly significant effect (OR [95% CI] = 2.053 [1.602-2.501], p = 0.002), with a number needed to treat NNT [95% CI] = 5.8 [4.1-23.0]. Despite a weak interaction with sex, we found a lack of heterogeneity in the treatment effect across specific subpopulations.
Conclusions: In the PREMILOC trial, the beneficial effect of prophylactic HC versus placebo on BPD-free survival in extremely preterm neonates was found to be greater when adjusted to baseline risks of BPD or death.
Registration Numbers: EudraCT number 2007-002041-20, ClinicalTrial.gov number NCT00623740.
Impact: Prophylactic low-dose hydrocortisone (HC) provided past evidence of a beneficial effect in improving survival without BPD in infants born extremely preterm. Adjustment for baseline risks of BPD or death might substantially increase the precision of the HC effect size. The beneficial effect of prophylactic HC vs placebo on BPD-free survival in extremely preterm neonates was found to be greater when adjusted to baseline risks of BPD or death. We evidenced a lack of heterogeneity in the treatment effect in specific subpopulations despite some weak interaction with sex.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798883 | PMC |
http://dx.doi.org/10.1038/s41390-023-02785-x | DOI Listing |
Pediatr Res
January 2025
Department of Pediatrics, Hospital Universitario Materno-Infantil de Canarias, Las Palmas de Gran Canaria, Spain.
Background: Randomized controlled trials (RCTs) have failed to demonstrate the beneficial effects of the pharmacological treatment of patent ductus arteriosus (PDA) in preterm infants. We conducted a Bayesian model averaged (BMA) meta-analysis of RCTs comparing the pharmacological treatment of PDA with placebo or expectant treatment.
Methods: We searched for RCTs including infants with gestational age (GA) ≤ 32 weeks and with a rate of open-label treatment of less than 25% in the control arm.
Eur J Pediatr
January 2025
Neonatal Research Network of Japan, Shinjuku, Tokyo, 163-1030, Japan.
Advancements in perinatal care have improved survival rates of extremely preterm infants born at 22 to 23 weeks of gestation, thus introducing new ethical challenges associated with their treatment. Therefore, we reviewed the epidemiological prognosis, treatment evolution, and ethical considerations associated with the care of preterm infants at the limit of viability. We comprehensively searched PubMed to find relevant English-language articles published between January 2014 and July 2024.
View Article and Find Full Text PDFEarly Hum Dev
January 2025
Department of Women and Children's Health, St Thomas' Hospital, King's College London, London, UK; Department of Perinatal Imaging, St Thomas' Hospital, King's College London, London, UK.
Objectives: The aim of this study was to utilise T2* relaxometry (an indirect method of quantifying tissue oxygenation) to assess the fetal thymus in uncomplicated pregnancies throughout gestation and in a cohort of fetuses that subsequently deliver very preterm.
Methods: A control group of participants with low-risk pregnancies were recruited and retrospectively excluded if they developed any pregnancy related complications after scanning. Participants were recruited who were deemed to be at very high risk of delivery prior to 32 weeks' gestation and retrospectively excluded if they did not deliver prior to this gestation.
PEC Innov
June 2025
Faculty of Nursing, University of Calgary, PF3280C, 2500 University Drive, NW Calgary, AB T2N 1N4, Canada.
Objective: To compare direct, non-medical out-of-pocket expenditures (OOPE) between mothers receiving Alberta Family Integrated Care (FICare™) versus standard care (SC) during their infant's neonatal intensive care unit (NICU) admission and explore factors influencing spending extremes.
Methods: In this exploratory, concurrent mixed-methods sub-study, we compared mother-reported OOPE from Alberta FICare™ and SC parent journals. We thematically analyzed hand-written notes from 30 journals with the highest and lowest 5 % of OOPE.
J Perinatol
January 2025
Neonatal Intensive Care Unit, Shenzhen Maternity & Child Healthcare Hospital, Southern Medical University, Shenzhen, 518028, Guangdong Province, China.
Objective: The aim of this study was to examine the predictive value of the lung ultrasound score (LUS) for successful extubation in preterm infants born at ≤25 weeks.
Methods: This was a single-center, prospective cohort study. Preterm infants with gestational age (GA) ≤ 25 weeks who received invasive mechanical ventilation (IMV) for ≥72 h were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!